Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit

INTERPACE BIOSCIENCES, INC.

2024-Q3 EPS reported $0.87 revenue$34,610,000

Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.
Operating income $1.9M vs operating loss of $0.02M a year ago; adjusted EBITDA $2.1M vs $0.4M.
Income from continuing ops $1.4M vs loss of $0.5M; gross margin 61% up from 55%.
Cash collections $11.3M (+15% YoY); cash $2.1M after $6.6M debt paydown; 18th consecutive quarter of YoY volume growth.
Company interviewing equity research partners and investment bankers for capital raise and potential Nasdaq listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.